CURRICULUM VITAE

HAYDAR CELIK, Ph.D.

Postdoctoral Research Fellow

Address: **** ********* ****, **, ******** Building, Room: E320, Department of Oncology,

Georgetown University Medical Center, Washington DC, 20057

Phone: 301-***-****

E-mail: acyuqs@r.postjobfree.com OR acyuqs@r.postjobfree.com

SUMMARY

I have a specific expertise in the development of small molecule inhibitors for targeted therapy of pediatric

cancers from my postdoctoral studies and a strong background in drug metabolism from my graduate work.

EDUCATION

2002 2008 Ph.D., Dept. of Biochemistry, METU, Ankara, Turkey

1999 2002 M.Sc., Dept. of Biochemistry, METU, Ankara, Turkey

1994 1999 B.Sc. with high honor, Dept. of Biological Sciences, METU, Ankara, Turkey

METU: Ranked 85th in World University Rankings 2015 based on Times Higher Education

EMPLOYMENT

08/12 - Current Georgetown University Medical Center, Dept. of Oncology, Washington DC, USA

Postdoctoral Research Fellow

02/11 08/12 Dept. of Basic Pharm. Sciences, Faculty of Pharmacy, Erciyes Univ., Kayseri, Turkey

Assistant Professor

11/09 02/11 Dept. of Food Engineering, Erciyes Univ., Kayseri, Turkey

Assistant Professor

04/08 11/09 Dept. of Food Engineering, Erciyes Univ., Kayseri, Turkey

Research Assistant

11/99 04/08 Dept. of Biological Sciences, METU, Ankara, Turkey

Research Assistant

HONORS & AWARDS

2013 The two year sponsored membership in AAAS/Science, the AAAS/Science

Program for Excellence in Science

2012 Prof. Mariapia Viola Magni EBTNA Award for The Second Best Oral

Presentation, Eurobiotech Agricultural Biotechnology Symposium, 12 14 April, 2012,

Kayseri, Turkey

1999 Graduation with a high honor degree, Dept. of Biology, METU, Ankara, Turkey,

(ranked 5th among 63 graduates)

1996 1999 Undergraduate Scholarship for the Education of Young Scientists, The Scientific

and Technological Research Council of Turkey (TUBITAK)

1994 Graduated as top student in Karatay High School Class of 1994 (Konya-Turkey)

PUBLICATIONS

Peer Reviewed Articles (in reverse chronological order)

1. Celik H, Sciandra M., Flashner B., Gelmez E., Kayraklioglu N., Allegakoen DV., Petro JR., Conn EJ., Hour

S., Han J., Oktay L., Tiwari PB., Hayran M., Cristina Manara M., Toretsky JA., Scotlandi K., Uren A.

(2016) First in class small molecule inhibitors of CD99 as novel therapeutics for Ewing sarcoma.

(Submitted to The Journal of Biological Chemistry)

2. Minas T.Z., Surdez D., Javaheri T., Tanaka M., Howarth M., Kang H.J., Han J., Han Z.Y., Sax B., Kream

B.E., Hong S.H., Celik H., Tirode F., Tuckermann J., Toretsky J.A., Kenner L., Kovar H., Lee S., Sweet

Cordero E.A., Nakamura T., Moriggl R., Delattre O., Uren A. (2016) Combined experience of six

independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget, (May 15;

doi:10.18632/oncotarget.9388).

3. Celik H., Bulut G., Han J., Graham G.T., Minas T.Z., Conn E.J., Hong S.H., Pauly G.T., Hayran M., Li X.,

Ozdemirli M., Ayhan A., Rudek M.A., Toretsky J.A., Uren A. (2016) Ezrin inhibition up regulates stress

response gene expression. The Journal of Biological Chemistry, 291(25), 132**-*****.

4. Kont Saygideger Y., Minas T.Z., Jones H., Hour S., Celik H., Temel I., Han J., Atabey N., Erkizan H.V.,

Toretsky J.A., ren A. (2016) Ezrin enhances EGFR signaling and modulates erlotinib sensitivity in non

small cell lung cancer cells. Neoplasia, 18(2), 111 120.

5. Minas T.Z., Han J., Javaheri T., Hong S.H., Sclederer M., Kont Saygideger Y., Celik H., Muller K., Temel I.,

Ozdemirli M., Kovar H., Erkizan H.V Toretsky J.A., Kenner L., Moriggl R., Uren A. (2015) YK-4-279

effectively antagonizes EWS FLI1 induced leukemia in a transgenic mouse model. Oncotarget, 6(35),

376**-*****.

6. Celik H., Hong S.H., Colon Lopez D., Han J., Kont Saygideger Y., Minas T. Z., Swift M., Paige M., Glasgow

E., Toretsky J.A., Bosch J., Uren A. (2015) Identification of novel ezrin inhibitors targeting metastatic

osteosarcoma by screening open access malaria box. Molecular Cancer Therapeutics, 14(11), 2497 2507

(selected as the Main Highlight in the cover page).

7. Gutierrez J., Garc a Villa E., Ocadiz Delgado R., Cort s Malag n E.M., V zquez J., Roman Rosales A.,

Alvarez Rios E., Celik H., Romano M.C., Uren A., Lambert P.F., Gariglio P (2015) Human papillomavirus

type 16 E7 oncoprotein upregulates the retinoic acid receptor beta expression in cervical cancer cell lines

and K14E7 transgenic mice. Molecular and Cellular Biochemistry, 408(1), 261 272.

8. Celik H., Sajwan K.P., Selvanathan S.P Marsh B.J., Pai A.V Kont Saygideger Y., Han J., Minas T., Rahim

S., Erkizan H.V Toretsky J.A., Uren A. (2015) Ezrin binds to DEAD box RNA helicase DDX3 and

regulates its function and protein level. Molecular and Cellular Biology, 35(18): 3145 3162.

9. Rahim S., Minas T., Hong S.H., Justvig S., Celik H, Kont Saygideger Y., Han J., Kallarakal A.T., Kong Y.,

Rudek M.A., Brown M.L., Kallakury B., Toretsky J.A., Uren A. (2014) A small molecule inhibitor of ETV1,

YK 4 279, prevents prostate cancer growth and metastasis in a mouse xenograft model. PloS ONE, 9(12):

e114260, DOI: 10.1371/journal.pone.0114260.

10. Cort s Malag n C.M., Bonilla Delgado J., D az Ch vez J., Hidalgo Miranda A., Romero Cordoba S., ren

A., Celik H, McCormick M., Mungu a Moreno J.A., Ibarra Sierra E., Escobar Herrera J., Lambert P.F.,

Mendoza Villanueva D., Bermudez Cruz R.M. and Gariglio P (2013) Gene expression profile regulated by

the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology, 447(1 2), 155 165.

11. Celik H. (Corresponding Author), Kosar M., Arinc E. (2013) In vitro effects of myricetin, morin,

apigenin, taxifolin, catechin, epicatechin, naringenin and naringin on cytochrome b5

reduction by purified NADH cytochrome b5 reductase. Toxicology, 308, 34 40.

12. Celik H., Arinc E. (2013) Evaluation of bioreductive activation of anticancer drugs idarubicin and

mitomycin C by NADH cytochrome b5 reductase and cytochrome P450 2B4. Xenobiotica, 43(3), 263

275.

13. Celik H. (Corresponding Author), Kosar M. (2012) Inhibitory effects of dietary flavonoids on purified

hepatic NADH cytochrome b5 reductase: structure activity relationships. Chemico Biological

Interactions, 197(2 3), 103 109.

14. Celik H. (Corresponding Author), Arinc E. (2010) Evaluation of the protective effects of quercetin,

rutin, resveratrol, naringenin and trolox against idarubicin induced DNA damage. Journal of Pharmacy

and Pharmaceutical Sciences, 13(2), 231 241.

15. Celik H.,, Arinc E. (2008) Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage

by NADPH cytochrome P450 reductase and its potential role in the antitumor effect. Journal of

Pharmacy and Pharmaceutical Sciences, 11(4), 68 82.

16. Arinc E., Celik H. (2002) Biochemical characteristics of purified beef liver NADPH cytochrome P450

reductase. Journal of Biochemical and Molecular Toxicology, 16 (6), 286 297.

Opinion Articles

17. Erkoc F., Sepici Din el A., Kayr n L., zkan Y., Eksioglu S., Yuksel M., Haklar G., Yavuz O., Celik H,

Konuk M., Kurban S., Uysal H., Kisa U., Bodur E., Selvi M., Akca G., Simsek B. (2013) The

multidisciplinary approach to biochemistry laboratory education. Turkish Journal of Biochemistry,

38(4), 506 512.

PROFESSIONAL SKILLS

Molecular Biology Techniques

PCR/Quantitative real time PCR

In vitro plasmid DNA damage and COMET assay

Design of luciferase gene reporter constructs reporter assays

Site directed mutagenesis

Use of siRNA/shRNA constructs for post transcriptional silencing

Gateway cloning, PCR&RE based cloning

Microarray gene expression analysis

Biochemical Techniques

Protein purification, colon chromatography techniques, AKTA

Electrophoretic techniques: SDS PAGE, coomassie & silver staining

Immunoprecipitation/Western blot

Cell free in vitro synthesis of proteins

ELISA

Enzyme characterization and kinetics

Enzyme inhibition kinetics

Enzyme activity measurements (spectrophotometric, spectrofluometric)

Biacore (SPR) system for monitoring biomolecular interactions

Cell Biology Techniques

Advanced mammalian and insect cell culture

Conditional Reprogrammed Cell (CRC) culture

Cellular apoptosis/cytotoxicity, proliferation assays

Roche xCELLigence & Essen Biosciences IncuCyte Zoom cell monitoring systems

Cell based assays (cell motility, cell migration and cell invasiveness)

Rec. protein expression and purification in mammalian and insect cells expression systems

Stable cell line production

Microbiology Techniques

Culture, selection and storage of bacterial cells

Bacterial transformation with plasmids

Rec. protein expression and purification in bacterial expression systems

Animal Handling

Handling of laboratory animals (injection, drawing blood,

survival surgery etc.)

Ex vivo pulmonary metastasis (PUMA) assay

In vivo transgenic and xenograft mouse models

Production of polyclonal antibodies against purified proteins in rabbit

RESEARCH EXPERIENCE

Postdoctoral Research Fellow (Prof. Aykut Uren Group) 2012 Present

Georgetown University Medical Center, Dept. of Oncology

Development of first in class small molecule inhibitors of ezrin in osteosarcoma: Studied

molecular mechanisms underlying the anti metastatic effects of small molecule inhibitors of ezrin

developed for targeted therapy of osteosarcoma metastasis. Discovered a novel molecular function for

ezrin in gene expression and regulation of stress granule dynamics that is distinct from its known

functions at the plasma membrane as a cytoskeletal scaffolding protein. Studied the PK of the anti ezrin

compounds, developed a PD marker for compound activity and validated their anti metastatic effects in

a transgenic mouse model of osteosarcoma (Mol Cell Biol, 2015 & J Biol Chem, 2016). Discovered

novel small molecule inhibitors of ezrin through screening open access Malaria Box ( Mol Cancer Ther,

2015; highlighted in the cover page ). Generated data, designed experiments, directed data analysis

and wrote the manuscripts.

Development of first in class small molecule inhibitors of CD99 in Ewing sarcoma: Discovered

two FDA approved drugs as the novel small molecule inhibitors of CD99 that selectively inhibit Ewing

sarcoma growth (manuscript submitted to The Journal of Biological Chemistry). Generated data,

designed experiments, directed data analysis and wrote the manuscript.

Development of first in class small molecule inhibitor for ETS transcription factors: This project

discovered that a small molecule inhibitor of EWS FLI1 oncoprotein in Ewing sarcoma is also a potent

inhibitor of ETV1 and inhibits both the primary tumor growth and metastasis of fusion positive prostate

cancer in mouse xenograft models. In a second study, our group also demonstrated the in vivo

therapeutic efficacy and potential side effects of this inhibitor in a transgenic mouse model with EWS

FLI1 induced leukemia. Contributed to these projects specifically by technical expertise, analyzing data

& intellectual discussion (PloS One, 2014 & Oncotarget, 2015).

Other (Role of ezrin in non small cell lung cancer & Ewing sarcoma mouse model): The first

project identified that ezrin enhances EGFR signaling and nuclear transport of EGFR in NSCLC cell

lines, and the anti ezrin compound demonstrates synergistic interaction with an EGFR inhibitor,

erlotinib. The second project aimed to develop a transgenic mouse that develops spontaneous ES driven

by EWS FLI1 expression. Contributed to these projects specifically by technical expertise, analyzing data

& intellectual discussion, and in writing of the manuscripts (Neoplasia, 2015 & Oncotarget, 2016).

Contributed Projects:

Cervical cancer Project: In collaboration with Dr. Patricio Gariglio from CINVESTAV IPN, Mexico.

The project aimed to demonstrate the differentially expressed genes induced by the human papilloma

virus 16 (HPV16) E7 oncoprotein and/or 17 estradiol in cervical tissue of transgenic mouse model of

cervical cancer. Specifically contributed to this project by demonstrating the effect of HPV16 E7

oncoprotein and/or 17 estradiol on human S100 A9 and RAR beta expression in human primary and

HPV16 E7 transformed keratinocytes (Virology, 2013 & Mol Cell Biochem, 2015).

Assistant Professor (Independent Researcher) 2009 2012

Erciyes University, Faculty of Pharmacy, Kayseri, Turkey

Interaction of dietary flavonoids & microsomal drug metabolizing enzymes: Characterized, for

the first time, the structure activity relationships of dietary flavonoids on the activity of purified hepatic

microsomal cytochrome b5 reductase cytochrome b5 system (Chem Biol Interact, 2012 & Toxicology,

2013). Generated data, designed experiments, directed data analysis and wrote the manuscripts.

Graduate Student (M.Sc. & Ph.D. Advisor: Prof. Emel Arinc) 1999 2008

METU, Ankara, Turkey

Ph.D. Thesis: Studied the role of drug metabolizing enzymes in reductive bioactivation of anticancer

drugs idarubicin and mitomycin C responsible for their antitumor effects by purifying the enzymes from

several mammalian tissues and species. Identified cytochrome P450 reductase but not cytochrome b5

reductase as the key enzyme in bioactivation of idarubicin and mitomycin C to DNA damaging

cytotoxic/genotoxic species. Demonstrated that human hepatic cytochrome P4502B4 isozyme

potentiates the cytotoxic activity of idarubicin

and mitomycin C in combination with cytochrome P450 reductase. Demonstrated the protective

effects of several phenolic antioxidants against the DNA damaging effect of idarubicin originating from

its cytochrome P450 reductase catalyzed bioactivation (J Pharm Pharm Sci, 2008, J Pharm Pharm

Sci, 2010 & Xenobiotica, 2013). Generated data, designed experiments, directed data analysis

and wrote the manuscripts.

M.Sc. Thesis: Studied the function and regulation of cytochrome P450 and other drug metabolizing

enzymes. Purified, for the first time, NADPH cytochrome P450 reductase enzyme from bovine liver

microsomes and characterized it with respect to its spectral, structural, kinetic and biocatalytic

properties (J Biochem Mol Toxicol, 2002). Generated data, designed experiments, directed data

analysis and wrote the manuscript.

Contact this candidate